drugset / Trial / NCT07431645

Pilot Study of Radiation-Induced Xerostomia Treatment With Allogeneic Mesenchymal Stromal Stem Cells

NCT07431645 ↗

Phase 1 Completed 10 enrolled Institute of Oncology Ljubljana
NaSingle-groupOpen-labelTreatment

Summary

This pilot interventional study evaluates the safety and preliminary efficacy of treatment with allogeneic mesenchymal stromal stem cells (MSCs) derived from umbilical cord tissue in patients with radiation-induced xerostomia after radiotherapy for head and neck cancer. Xerostomia is a frequent late adverse effect of radiotherapy and can significantly impair oral function and quality of life. Participants receive a single administration of allogeneic MSCs as the study intervention and are followed for clinical outcomes. The study evaluates safety, salivary gland function, subjective xerostomia symptoms, and imaging-based changes in salivary gland tissue. The results of this pilot study may support the development of regenerative treatment strategies for radiation-induced salivary gland damage.

Timeline

Start
2023-04-01
Primary completion
2025-10-10
Completion
2025-10-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Allogeneic Mesenchymal Stromal Cells (MSC) Cell therapy — —